Jeanna Welborn, M.D.

Jeanna Welborn, M.D.

Specialties

Benign and Malignant Hematology

Thrombosis

Leukemia

Department

Internal Medicine

UC Davis Comprehensive Cancer Center

Title

  • Professor (HSCP)

Reviews

To see if Jeanna Welborn is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:
800-362-5566
916-734-5959

Additional Phone Numbers

Clinic Fax: 916-703-5265
Clinic Referral Phone: 916-703-5210
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Clinical Interests

Jeanna L. Welborn directs the Cytogenetics and Bone Marrow Labs and is an expert in myelodysplasia and leukemia. She concentrates on providing psychosocial support for patients through innovative therapies and outpatient disease management programs.

Research/Academic Interests

Dr. Welborn's research encompasses study of acute leukemias, oncogenes, cytogenetics and molecular epidemiology of cancer.

Division

Hematology and Oncology
Hereditary Cancer Program

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Education

M.D., University of Texas, Southwestern Medical School, Dallas TX 1982

B.A., Austin College, Sherman TX 1976

Internship: Internal Medicine, Good Samaritan Medical Center, Portland OR 1982-1985

Residency

Internal Medicine, Good Samaritan Medical Center, Portland OR 1982-1985

Fellowships

Hematology/Oncology, UC Davis Medical Center, Sacramento CA 1985-1988

Clinical Cytogenetics, UC Davis Medical Center, Sacramento CA 1987-1988

Board Certifications

American Board of Internal Medicine,

American Board of Internal Medicine, Hematology,

American Board of Internal Medicine, Medical Oncology,

American Board of Medical Genetics - Clinical Cytogenetics,

Professional Memberships

Southwest Oncology Group, Leukemia Committee

Southwest Oncology Group, Pathology Committee

Honors and Awards

UC Davis Health, Internal Medicine Clinician Award, 2017

Who's Who of American Small Colleges, 1976

Select Recent Publications

For a comprehensive list of Dr. Welborn's publications, please click here (opens new window).

Li T, Stollenwerk N, Mans N, Welborn J, Lam K. Safety and Efficacy of Osimertinib in Treating a Metastatic Lung Cancer Patient with Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations. JCO Precision Oncology. 2018;2:1-7.

Su RJ, Jonas BA, Welborn J, Gregg JP, Chen M. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: A novel variant of myeloid proliferative neoplasm with eosinophilia. Hum Pathol (NY). 2016 Sep;5:6–9. doi:10.1016/j.ehpc.2015.10.001.

Tuscano JM, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, Welborn J, O'Donnell RT. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014 May;165(3):375-81. doi:10.1111/bjh.12755. Epub 2014 Mar 7.

Welborn J, Fenner S, Parks R. Features of polycythemia vera in the 8p12 myeloproliferative syndrome. Cancer Genet Cytogenet. 2010 May;199(1): 53-5. doi:10.1016/j.cancergencyto.2010.01.013.

Welborn J, Fenner S, Parks R. Angioleiomyoma: a benign tumor with karyotypic aberrations. Cancer Genet Cytogenet. 2010 Jun;199(2):147-8. doi:10.1016/j.cancergencyto.2010.01.022.

Welborn J. Review: erythropoietin or darbepoetin for anemia in patients with cancer produces both benefits and harms with no increase in survival. ACP J Club. 2007 Jan-Feb;146(1): 6.

Lakshmunarayanan R, Konia T, Welborn J. Fibrous Hamartoma of Infancy: A Case Report with Associated Cytogenetic Findings. Arch Pathol Lab Med. 2005 Apr;129(4): 520-2. doi:10.1043/1543-2165(2005)129<520:FHOIAC>2.0.CO;2.

Welborn J. Oral and intravenous antibiotics do not differ for effeciveness in febrile neutropenic patients with cancer. ACP J Club. 2005 Mar-Apr;142(2):32.

Welborn J, Jenks H, Taplett J, Walling P. High-grade neuroendocrine carcinomas display unique cytogenetic aberrations. Cancer Genet Cytogenetics. 2004 Nov;155(1): 33-41. doi:10.1016/j.cancergencyto.2004.03.001.

Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman C, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004 Sep-Oct;10(5):294-300. doi:10.1097/00130404-200409000-00006.